Abstract

3567Background: The objective of this phase II trial wasto compare efficacy of Pmab plus FOLFIRI and Bmab plus FOLFIRI as second-line chemotherapy for patients (pts) with wild-type (WT) KRAS exon 2...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408).
Scott D Patterson ... Salvatore Siena
Journal of Clinical Oncology | VOL. 31
Scott D Patterson, et. al.Scott D Patterson ... Salvatore Siena
20 May 2013
Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
Tomohiro Nishina ... Hiroyuki Okuda
Journal of Clinical Oncology | VOL. 36
Tomohiro Nishina, et. al.Tomohiro Nishina ... Hiroyuki Okuda
01 Feb 2018
O-0012 - Updated Results of the Randomized Phase 2 Impact Trial: Maintenance with TLR-9 Agonist Mgn1703 Vs Placebo in Patients with Metastatic Colorectal Carcinoma (MCRC)
Hans-Joachim Schmoll ... Werner Scheithauer
Annals of oncology : official journal of the European Society for Medical Oncology | VOL. 24
Hans-Joachim Schmoll, et. al.Hans-Joachim Schmoll ... Werner Scheithauer
01 Jun 2013
PEAK: A Randomized, Multicenter Phase II Study of Panitumumab Plus Modified Fluorouracil, Leucovorin, and Oxaliplatin (mFOLFOX6) or Bevacizumab Plus mFOLFOX6 in Patients With Previously Untreated, Unresectable, Wild-Type KRAS Exon 2 Metastatic Colorectal Cancer
Lee S Schwartzberg ... Hua Yu
Journal of Clinical Oncology | VOL. 32
Lee S Schwartzberg, et. al.Lee S Schwartzberg ... Hua Yu
31 Mar 2014
View more papers

More From: Journal of Clinical Oncology

Paper Title
Journal
Date
Author
Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial.
Alexios Matikas ...
Journal of Clinical Oncology | VOL. -
Alexios Matikas, et. al.Alexios Matikas ...
17 Jul 2024
Lymphoma Classifications, How to Develop a Future Unified Taxonomy.
Elias Campo ... Reiner Siebert
Journal of Clinical Oncology | VOL. -
Elias Campo, et. al.Elias Campo ... Reiner Siebert
17 Jul 2024
Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.
Brian C Shaffer ... Monzr M Al Malki
Journal of Clinical Oncology | VOL. -
Brian C Shaffer, et. al.Brian C Shaffer ... Monzr M Al Malki
17 Jul 2024
Genetic Counseling, Testing, and Family Communication Into Survivorship After Diagnosis of Breast Cancer.
Steven J Katz ... Allison W Kurian
Journal of Clinical Oncology | VOL. -
Steven J Katz, et. al.Steven J Katz ... Allison W Kurian
15 Jul 2024
View more papers